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ABSTRACT
XRCC1 is a critical scaffold protein that orches-
trates efficient single-strand break repair (SSBR).
Recent data has found an association of XRCC1
with proteins causally linked to human spinocere-
bellar ataxias—aprataxin and tyrosyl-DNA phos-
phodiesterase 1—implicating SSBR in protection
against neuronal cell loss and neurodegenerative
disease. We demonstrate herein that shRNA
lentiviral-mediated XRCC1 knockdown in human
SH-SY5Y neuroblastoma cells results in a largely
selective increase in sensitivity of the nondividing
(i.e. terminally differentiated) cell population to the
redox-cycling agents, menadione and paraquat; this
reduced survival was accompanied by an accumula-
tion of DNA strand breaks. Using hypoxanthine–
xanthine oxidase as the oxidizing method, XRCC1
deficiency affected both dividing and nondividing
SH-SY5Y cells, with a greater effect on survival
seen in the former case, suggesting that the spec-
trum of oxidative DNA damage created dictates the
specific contribution of XRCC1 to cellular resis-
tance. Primary XRCC1 heterozygous mouse cere-
bellar granule cells exhibit increased strand break
accumulation and reduced survival due to increased
apoptosis following menadione treatment. More-
over, knockdown of XRCC1 in primary human fetal
brain neurons leads to enhanced sensitivity to
menadione, as indicated by increased levels of
DNA strand breaks relative to control cells. The
cumulative results implicate XRCC1, and more
broadly SSBR, in the protection of nondividing neu-
ronal cells from the genotoxic consequences of
oxidative stress.
INTRODUCTION
Base excision repair (BER) operates as the primary path-
way for resolving small base modiﬁcations, abasic sites
and several forms of DNA single-strand breaks (SSBs)
(1). Such damage arises upon oxidation or alkylation of
DNA, or by spontaneous hydrolytic decay (e.g. deamina-
tion of cytosine to uracil). BER is typically initiated by
removal of a target base by a speciﬁc DNA glycosylase,
which generates an abasic site product (AP site). The AP
site is then processed either by an AP endonuclease, which
incises the phosphodiester bond 50 to the lesion to create a
SSB with an abnormal 50-deoxyribose phosphate (dRP)
residue and a conventional 30 hydroxy (OH) terminus, or
by a bifunctional DNA glycosylase, which cleaves 30 to the
abasic site to produce a SSB with a normal 50 phosphate
(P) group and an atypical 30 a,b unsaturated aldehyde or
30 P fragment. The resulting termini are processed accord-
ingly to generate 30 OH and 50 P ends to allow gap-ﬁlling
and nick ligation (2,3).
The polymerization step of BER involves either a short-
or long-patch synthetic mechanism (4). In short-patch
BER, DNA polymerase b (Pol b) adds a single nucleotide
to ﬁll the gap and removes the 50-dRP group at the SSB
site. The nick is then sealed by DNA ligase IIIa (LIG3) in
complex with the scaﬀold protein XRCC1 (X-ray cross-
complementing 1) to re-generate an intact strand. Long-
patch BER involves the synthesis of a patch of 2–10nt and
the formation of a displaced 50-ﬂap structure. This path-
way engages the proliferating cell nuclear antigen (PCNA)-
dependent polymerases Pol d/", or Pol b, in conjunction
with the 50-ﬂap endonuclease (Fen1) and DNA ligase I.
An important aspect of BER is the processing of
abnormal DNA 30 or 50 terminal blocking groups. Such
lesions can arise by free radical attack of DNA, or as
products or intermediates of speciﬁc enzymatic reactions
(see for instance above) (3). In order for repair to be suc-
cessfully completed, abnormal SSB ends, which prevent
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and 30 OH groups. Often considered a subpathway of
BER, SSBR and its complement of proteins, has evolved
to remove abnormal DNA terminal ends. XRCC1 is a key
component of SSBR, as cells defective in this nonenzy-
matic scaﬀold protein show reduced SSBR, enhanced sen-
sitivity to DNA-damaging agents that produce SSBs, and
increased sister chromatid exchange (5). Notably, XRCC1
has been shown to possess important and distinct roles in
SSBR in both the G1 and S phase of the cell cycle, pre-
sumably reﬂecting its contribution to global and replica-
tion-coupled repair, respectively (6,7). Mice devoid of
XRCC1 die early in embryogenesis, indicating an essential
role for this protein in animal development (8).
XRCC1 coordinates several key enzymatic factors at
sites of SSBs, including the DNA polynucleotide kinase–
phosphatase (PNKP), Polb and LIG3a, via direct physical
interactions (9). Recent evidence also indicates critical
associations of XRCC1 with two proteins, aprataxin and
tyrosyl-DNA phosphodiesterase 1 (TDP1), which are
defective in the recessive hereditary spinocerebellar atax-
ias, ataxia with oculomotor apraxia (AOA1) and spino-
cerebellar ataxia with axonal neuropathy (SCAN1),
respectively (10–14). Aprataxin is responsible for remov-
ing obstructive 50 adenylate groups that arise as abortive
DNA ligation intermediates (10), as well as 30 phosphate
and 30 phosphoglycolate groups that are products of free
radical attack of DNA (15). TDP1 functions to excise
abortive 30 topoisomerase 1 (Top1)-DNA intermediates,
which occur when Top1 becomes irreversibly trapped on
DNA during its strand cleavage reaction, most frequently
at sites of nearby DNA damage (16,17).
As the above neurodegenerative disorders are character-
ized by cerebellar ataxia and peripheral axonal neuropa-
thy without nonneurological symptoms, such as cancer
predisposition (18,19), it has been proposed that SSBR
defects give rise to neurological dysfunction selectively
because nondividing cells, particularly neuronal cells
which are highly metabolically active, accumulate a large
number of SSBs that have the potential to block transcrip-
tion and induce apoptosis (20). Conversely, SSBR-deﬁ-
cient dividing cells could potentially resolve SSBs
eﬃciently and accurately using alternative mechanisms,
such as replication-dependent homologous recombination
(HR). Synergism between HR and SSBR has recently been
demonstrated, as HR-deﬁcient BRCA mutant cell lines
are inviable upon inhibition of the strand break response
protein, poly (ADP) ribose polymerase (PARP-1) (21–23).
These observations have prompted the hypothesis that
SSBR may have a more prominent role in nondividing
tissue. Using XRCC1 as a representative of the global
SSBR response, we investigated herein the contribution
of this process to oxidative stress resistance in both divid-
ing and nondividing neural cell populations.
MATERIALS AND METHODS
Differentiation of SH-SY5Y cells
Twenty to thirty percent conﬂuent SH-SY5Y cells in a
T-75 ﬂask were treated with 10mM retinoic acid (RA) in
high glucose DMEM media (Gibco/Invitrogen, Carlsbad,
California, USA) with 1% penicillin–streptomycin and
10% fetal bovine serum (FBS) for 5 days. The RA
media was replaced with serum free DMEM with 10ng/
ml brain derived neurotrophic factor (BDNF, Alamone
Labs, Jerusalem, Israel), and diﬀerentiation was allowed
to continue for another 5 days.
Preparationoflentivirus stock and infection of SH-SY5Y cells
An XRCC1-speciﬁc TRC shRNA-pLKO.1 plasmid con-
struct (clone ID TRCN0000007913; Open Biosystems,
Huntsville, Alabama, USA) or a negative control scram-
ble shRNA-pLKO.1 construct (plasmid #1864; Addgene,
Cambridge, Massachusetts, USA) was co-transfected with
the packaging plasmid pCMV-dr8.2 dvpr (plasmid #8455;
Addgene) and the envelop plasmid pCMV-VSV-G
(plasmid #8454; Addgene) into human embryonic kidney
293T cells maintained in the media above using lipofecta-
mine (Invitrogen) and Optimem (Gibco). Media was
replaced after 24h and virus-containing media was col-
lected at 48 and 72h posttransfection, and ﬁltered using
a 0.45-micron PVDF membrane ﬁlter (Millipore, Billerica,
Massachusetts, USA).
A total of 1ml or 0.5ml of the above ﬁltered viral stock
was added per well of a 6-well plate to 70% conﬂuent
SH-SY5Y cells with 4mg/ml hexadimethrine bromide
(a.k.a. polybrene, Sigma, St. Louis, Missouri, USA).
After 24h, viral media was removed and fresh high glu-
cose DMEM media with 1% penicillin–streptomycin and
10% FBS was added. SH-SY5Y cells were selected after
another 24h in 2.1mg/ml puromycin (Sigma). Resistant
colonies were periodically checked for XRCC1 expression
using standard western blotting procedures. Antibodies
used were XRCC1 ab-1 or ab-3 (NeoMarkers-Thermo
Fisher Scientiﬁc Inc., Fremont, California, USA), and
b-actin or Lamin AC (Santa Cruz Biotechnology, Santa
Cruz, California, USA).
Survival assayforSH-SY5Y cells
Fifty thousand cells/well in a 96-well plate were treated
with menadione (1h), MMS (1h), arsenic trioxide (24h),
methyl viologen dichloride or paraquat (24h), or hypox-
anthine (at the indicated concentration, see Figures) plus
0.1U/ml xanthine oxidase (15min) in standard DMEM
media for replicating SH-SY5Y cells or in serum free-
BDNF media for the diﬀerentiated cells. Following treat-
ment, cells were incubated with 1:10 concentration of
WST-1 cell proliferation reagent (Roche, Pleasanton,
California, USA) in appropriate media for 4h at 378C.
Viability was scored using a BioRad microplate spectro-
photometer, with the number of viable cells proportional
to the OD 450nm reading. Percent survival for each dose
was calculated relative to the OD 450nm for the untreated
samples, which was assumed to represent 100% viability.
SSB measurement
The TUNEL assay, which employs terminal transferase to
detect all strand breaks, was modiﬁed to use DNA
Polymerase I (Pol I) to detect mainly SSBs (24). Pol
I-mediated biotin-dUTP nick-end labeling (PUNEL) of
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in situ apoptosis detection kit (Trevigen Inc.,
Gaithersburg, Maryland, USA). Brieﬂy, diﬀerentiated
SH-SY5Y cells, mouse cerebellar granule cells or human
fetal brain neuronal–glial cells were ﬁxed in 3.7% formal-
dehyde or 4% paraformaldehyde, and permeablized for
10min at room temperature with neuropore solution
(Trevigen). Samples were incubated with Pol I (New
England Biolabs, Ipswich, Massachusetts, USA) and
dNTPs, including biotin-dUTP (Trevigen), for 1h at
378C, followed by streptavidin–HRP solution and diami-
nobenzidine (DAB) or streptavidin–ﬂuor for detection of
DNA breaks. Slides were counterstained, dehydrated,
mounted in Permount and visualized by light microscopy.
Damage was estimated based on the intensity of DAB
staining, with increased intensity correlating with greater
damage. At least 100 cells were counted per treatment.
Extraction of primary cerebellar granule neurons from mice
Six- to eight-day-old pups from a timed mating between
an XRCC1 heterozygous male and a C57BL/6 wild-type
female mouse were sacriﬁced and the cerebellum isolated.
The cerebellum was then placed into Hibernate A medium
(Brain Bits LLC, Springﬁeld, Illinois, USA) and minced
into ﬁne pieces. The minced tissue was digested in Earle’s
balanced salt solution (EBBS) with 0.1% trypsin (Gibco),
4mg DNase (Sigma) and 3mM magnesium sulphate
(Sigma) for 15min at 378C. Following digestion, the
tissue was triturated by passing multiple times through a
22.5G sterile needle until a ﬁne suspension was obtained,
which was left at room temperature for 30min to sedi-
ment. The supernatant, containing the single cell solution,
was spun at 1000r.p.m. for 5min. The pellet was resus-
pended in neurobasal medium (Gibco) with 10% FBS,
10% horse serum, 0.5mM glutamine, 25mM potassium
chloride and 2% B-27 supplement. Cells were counted
using a Beckman Coulter Z1 Particle counter and plated
at 65000 cells per chamber of an 8-well poly-D-lysine
coated chamber slide (Becton Dickinson, Franklin
Lakes, New Jersey, USA), and incubated for 2h at 378C
to allow cells to attach. The media was then changed to
serum-free neurobasal medium containing 25mM KCl,
0.5mM L-glutamine and 2% B27 supplement and cells
were maintained in culture as speciﬁed.
Neuronal cell viability
Diﬀerentiated mouse cerebellar granule cells in neurobasal
maintenance medium (see above) for 7 days were treated
with varying concentrations of menadione for 1h in
EBBS, and diﬀerentially stained with 15mg/ml ﬂuorescein
diacetate, 5mg/ml propidium iodide (PI) and 2mg/ml
Hoechst in maintenance media for 5min at 378C.
The staining solution was washed oﬀ with PBS, and
cells were mounted in prolong gold antifade reagent
(Invitrogen), cured for 24h in the dark at room tempera-
ture, and visualized using a Zeiss Axiovert microscope at
20–40  magniﬁcation. Blue Hoechst was used to detect all
cells in the frame. Cells with a green ﬂuorescein staining
and without PI staining were counted as viable. Cells with
red PI staining were counted as dead. Approximately
50 cells were analyzed per group.
Neuronal cell apoptosis
Diﬀerentiated mouse cerebellar granule cells were treated
with menadione as above and then incubated with a
carboxyﬂuorescein labeled ﬂuormethyl ketone peptide
inhibitor of caspase (carboxyﬂuorescein FLICA apoptosis
detection kit, Immunochemistry Technologies LLC,
Bloomington, Minneapolis, USA) for 90min at 378C.
Cells were washed for 30min at 378C and stained with
0.5% V/V Hoechst for 5min at 378C. Slides were ﬁxed
in 3.7% buﬀered formaldehyde, mounted in Permount
(Fisher Scientiﬁc, Pittsburgh, Pennsylvania, USA) and
visualized using ﬂuorescence and light microscopy.
Activation of caspases in apoptotic cells results in the
binding of the inhibitor peptide and emission of green
ﬂuorescence. Cells stained with both carboxyﬂuorescein
and Hoechst were scored as apoptotic, and cells stained
with Hoechst only were scored as nonapoptotic. At least
100 cells per pup, per dose were counted.
Culture ofmixed human fetal brain neuronal–glial cultures
Human fetal neuronal–glial cultures were prepared as
described previously (25) from human fetal brain speci-
mens of 12–15 weeks gestational age, with consent from
women undergoing elective termination of pregnancy, as
approved by the Johns Hopkins University Institutional
Review Board. Isolated fetal neurons were resuspended in
Optimem with 5% heat inactivated FBS, 0.2  N-2 supple-
ment, penicillin G (100units/ml), streptomycin (100mg/ml)
and amphotericin B (0.25mg/ml) added. Cells were main-
tained in tissue culture ﬂasks for at least 4 weeks, then
plated into 6-well plates and 35mm glass bottom dishes
(MatTek Corp., Ashland, Massachusetts, USA).
Lentiviral infection was performed for 24h in a 6-well
plate essentially as above, except that polybrene was
omitted. Human fetal brain cells were maintained for
three additional days in regular maintenance medium
(Optimem plus supplements) and then ﬁxed with 4% par-
aformaldehdye in PBS for 15min at room temperature for
immunoﬂuorescence detection of XRCC1. One batch of
cells was treated with varying doses of menadione for 1h,
before ﬁxation and used in a PUNEL assay for detection
of DNA damage (see above).
Immunocytochemistry ofhuman fetal brain neuronal-glial
cultures
Paraformaldehyde ﬁxed neurons were blocked in 5% goat
serum at room temperature for 30min and separately
incubated with either a primary XRCC1 antibody
(clone 33-2-5; NeoMarkers-Thermo Fisher Scientiﬁc
Inc.) or a Tuj-1 (neuronal class III b-tubulin) antibody
(Sigma) at room temperature for 45min. Cells were
washed with PBS and incubated at room
temperature for an additional 45min with either an
Alexa ﬂuor 488 goat-anti mouse secondary antibody
(Invitrogen) for detection of XRCC1 or an Alexa ﬂuor
goat anti-mouse 546 secondary antibody (Invitrogen) for
identiﬁcation of neurons. Excess secondary antibody was
Nucleic Acids Research, 2008, Vol. 36, No. 15 5113washed oﬀ with PBS, samples were mounted in prolong
gold antifade reagent with DAPI (Invitrogen) and visua-
lized at 20–40  magniﬁcation using a Zeiss Axiovert
microscope with detection ﬁlters for DAPI, FITC and
Cy3 ﬂuorescence. Samples stained with Tuj-1 were further
examined for strand breaks and apoptosis using the
TUNEL assay (Trevigen) as described above, except that
a streptavidin-ﬂuor secondary antibody was used for
detection of damage and apoptosis.
RESULTS
The SH-SY5Y cell line is a third generation subclone of
the SK-N-SH line established from a bone marrow biopsy
of a neuroblastoma patient. The cells are neuronal in
origin, arising from the neural crest region of the sympa-
thetic nervous system with both dividing and nondividing
sub-populations. The dividing cells can be morphologi-
cally and functionally diﬀerentiated into a nondividing
neuron-like state upon treatment with various reagents
such as 12-O-tetradecanoyl-phorbol-13-acetate, RA or
staurosporine (26,27). This feature makes this cell line
especially suitable for studies on the diﬀerential role of
speciﬁc pathways in dividing versus nondividing (a.k.a.
terminally diﬀerentiated) neural cell populations.
Morphologically, diﬀerentiation is characterized by the
extension of neurites with motile terminal growth cones,
which on contact with neighboring cells form an intricate
network or grid of connections. We initially chose RA to
induce diﬀerentiation (28), but were unable to achieve
complete diﬀerentiation, as indicated by a sub-population
of cells that continued to divide following several days of
RA treatment (data not shown). A subsequent treatment
after RA with BDNF in serum free media [as reported in
(29)] was therefore adapted and yielded a population of
almost exclusively nondividing cells used for subsequent
studies (Figure 1A).
Methods for down-regulation of XRCC1 were estab-
lished using an XRCC1 speciﬁc TRC shRNA-pLKO.1
plasmid construct and a lentiviral package and delivery
system as described in Materials and Methods section.
A scramble-shRNA (30) was used in the preparation of
a control virus for the simultaneous infection of a separate
batch of SH-SY5Y cells. Figure 1B shows the expression
of XRCC1 protein in the control (scramble) and XRCC1-
knockdown (XKD) shRNA replicating cells. Stable sup-
pression of the XRCC1 protein was achieved using the
targeting shRNA system, while the scramble-shRNA
infected cells retained XRCC1 expression.
To determine the functional consequence of XRCC1
down-regulation, we evaluated methyl methanesulfonate
(MMS) sensitivity. Figure 1C shows the results from a
WST-1 viability assay, in which XKD dividing cells were
hypersensitive to MMS, a phenotype that is characteristic
of XRCC1-deﬁcient mammalian cells (5). A 3- to 6-fold
hypersensitivity of the XKD cells to MMS when compar-
ing LD50 values (i.e. the concentration of genotoxin to
induce 50% cell killing) was conﬁrmed independently by
a colony survival assay (Figure 1D), and is consistent with
previoussiRNAtargetingstudiesinhumancells(13,31,32).
Figure 1. Diﬀerentiation of SH-SY5Y cells and generation of XKD cells. (A) Cellular diﬀerentiation of the SH-SY5Y cells was established using a
combination of RA and BDNF (see Materials and methods section). Diﬀerentiated cells (right) stop dividing, are morphologically distinct in
appearance from undiﬀerentiated dividing cells (left), and form distinct neurite processes (arrow) that create an intricate network of neuronal-
type connections. (B) Dividing SH-SY5Y cells were infected with a lentivirus bearing an XRCC1-targeting shRNA sequence or a control scramble
sequence. Infected cells were selected on the basis of puromycin resistance and expression of XRCC1 was analyzed regularly. Shown is a repre-
sentative western blot of XRCC1 protein expression in dividing XKD and control cells. b-actin was used as a loading control. (C) Functional down-
regulation of SSBR was veriﬁed via a WST-1 survival assay following treatment of dividing SH-SY5Y cells with MMS at the indicated doses for 1h
(see Materials and methods section). Percentage survival for XKD (open square) and control scramble (ﬁlled circle) cells was calculated as a
percentage of survival of untreated cells. Averages and SDs plotted are from two separate runs of three repeats each. (D) Down-regulation of
SSBR was independently veriﬁed using a colony formation assay. XKD (open square) or control (ﬁlled circle) SH-SY5Y dividing cells, which were
plated at 500 cells per well, were treated with the indicated doses of MMS for 1h. Following treatment, cells were washed with 1X PBS and allowed
to form colonies under standard growth conditions for about 15 days. Percentage survival was calculated as a percentage of colonies formed relative
to the untreated sample. Averages and SDs plotted are from three repeats.
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monitored for control and XKD cells and found to be
similar (Kulkarni and Wilson, unpublished observation).
We point out that the nondividing XKD cells were down-
regulated signiﬁcantly for XRCC1 protein expression and
exhibited  4-fold increase in sensitivity to MMS as well
(Figure 2). Finally, we note that Narciso et al. (33) recently
reported down-regulation of XRCC1 in diﬀerentiated
human skeletal muscle cells; however, analysis of expres-
sional changes of several DNA damage response genes
following RA-BDNF diﬀerentiation of SH-SY5Y neuro-
blastoma cells did not reveal down-regulation of XRCC1
protein expression (Kulkarni and Wilson, unpublished
observations), suggesting a cell type-speciﬁc regulation of
this gene product.
Role ofXRCC1 inoxidative stressresistance in dividing
and nondividing cells
Following establishment of the above methods, we exam-
ined the contribution of XRCC1 to oxidative stress resis-
tance in dividing and nondividing SH-SY5Y cells. We
chose oxidative stress as the damaging agent, since neuro-
nal cells, on account of their higher energy needs, are
likely to be subject to elevated oxidative tension in vivo
and hence increased oxidative DNA damage. Both divid-
ing and nondividing SH-SY5Y cell populations were
initially tested with the oxidizing agent menadione, a
redox-cycling quinone that undergoes a two step reduction
that leads to the production of superoxide radicals (34).
As seen from Figure 3A (WST-1 assay), the dividing popu-
lation of XKD or control cells showed a similar survival
response following menadione challenge, suggesting that
XRCC1 plays no observable role in oxidative stress resis-
tance in replicating SH-SY5Y cells. On the other hand, the
nondividing XKD cells (LD50 of  16mM) showed about
6-fold greater sensitivity to menadione as compared to
the control cells with an LD50 value of over 100mM
(Figure 3A). This ﬁnding suggests that the lack of XRCC1
and functional SSBR is selectively detrimental to the non-
dividing cell population, at least in the case of menadione.
We also note that, we observed a  2-fold increase in sensi-
tivity of nondividing, diﬀerentiated XKD cells following
menadione exposure when a 24-h recovery period was
incorporated as opposed to the immediate response mea-
sured in the assays above (Supplementary Figure 1).
To conﬁrm that the above diﬀerence in sensitivity is
related to a SSBR defect, we examined the recovery of
XKD and control nondividing cell populations to DNA
damage introduced by menadione. In particular, cells were
allowed to recover following menadione treatment in
drug-free media for  75min, at which time they were
stained for SSB accumulation using the adapted PUNEL
assay (see Materials and Methods section). These studies
showed little or no DAB staining (dark brown cells) in the
RA-BDNF diﬀerentiated control cells (Figure 3B), sug-
gesting eﬃcient repair and nearly complete recovery
from any DNA damage incurred; this observation is con-
sistent with the near 100% viability observed for these
cells after menadione treatment (Figure 3A). The nondi-
viding XKD cells, on the other hand, stained intensely for
labeled SSBs, indicating persistent DNA damage and non-
functional repair (Figure 3B). Additionally, these cells
appeared rounded up, and in some cases shrunken or
shriveled, suggesting that they might be apoptotic or
necrotic. Quantiﬁcation of the DAB-stained cells as a per-
cent of the total cells showed about a 4-fold increase in the
frequency of PUNEL positive cells (and by extension
SSBs) in the XKD nondividing cells relative to the control
cells at both menadione concentrations (Figure 3C).
We next tested the response of dividing and nondividing
control and XKD SH-SY5Y cells to other generators of
ROS, namely paraquat, arsenic and a xanthine oxidase-
hypoxanthine (XOH) system. As in the case of menadione,
treatment with paraquat, another redox cycling agent that
generates primarily superoxide (35), led to a more pro-
nounced increase in sensitivity of the XKD nondividing
cells ( 6-fold based on LD50), although elevated sensitiv-
ity of the dividing population was seen at the highest para-
quat concentration (Figure 4A). Arsenic treatment yielded
a similar response, whereby the nondividing XKD cells
were  4-fold more sensitive than the control cells, with
no hypersensitivity, and perhaps a slight increased resis-
tance, for the dividing cells (Figure 4B). Interestingly,
XOH treatment showed a disparate pattern of response
in that both dividing and nondividing XKD cells were
more sensitive to oxidative stress, with the greatest sensi-
tivity seen in the former situation (Figure 4C). As gleaned
from the survival data, it is noteworthy that terminal dif-
ferentiation (and perhaps the nondividing status) led to a
Figure 2. MMS sensitivity of nondividing XKD SH-SY5Y cells.
(A) Following establishment of undiﬀerentiated dividing XKD
SH-SY5Y cells, a population of these cells was diﬀerentiated with
RA and BDNF as described in Materials and methods section.
XRCC1 knock-down was maintained in these nondividing cells as
shown by western blotting (XKD). The control represents the scramble
shRNA–lentivirus infected SH-SY5Y cells. Denoted is the position of
XRCC1 protein and the Lamin AC loading control. (B) Diﬀerentiated,
nondividing XKD (open square) or control (ﬁlled circle) cells plated at
50000 cells/well in a 96-well plate were treated with the indicated doses
of MMS for 1h. Following treatment, cells were incubated with the
WST-1 reagent for 4h as described in Materials and methods section.
Viability at each dose was determined and calculated as a percent of the
reading obtained for untreated cells. Averages and SDs represent three
repeats of a representative experiment.
Nucleic Acids Research, 2008, Vol. 36, No. 15 5115general increase in stress resistance (to menadione, arsenic
and XOH treatments), an observation that is consistent
with the reported improvement in resistance of RA treated
SH-SY5Y cells to certain drugs and DNA damaging
agents (36,37).
Effectof XRCC1 deficiency on primary mouse and human
neuronalcell survival
To further investigate the role of XRCC1 in oxidative
stress resistance in nondividing neuronal cells, we
examined the response of XRCC1-deﬁcient primary cells
from both mouse and human in culture. First, we deter-
mined the eﬀect of menadione exposure on relative survi-
val, DNA damage accumulation and apoptosis of primary
cerebellar granule neurons from wild type or XRCC1 het-
erozygous 6- to 8-day-old mice. Mouse cerebellar granule
neurons are primary cells that are nondividing by nature,
and after 7 days in culture, have a phenotype of fully
diﬀerentiated neurons with an intricate neurite network
and synaptic contacts. We examined independent cell
populations isolated from four wild-type and three
Figure 3. Role of XRCC1 in stress resistance in dividing and nondividing cells. (A) Survival of XKD (open square) and control cells (ﬁlled circle) in
dividing (left) and nondividing (right) states, as estimated by a WST-1 survival assay following a 1h exposure to menadione as described in Materials
and methods section. Averages and SDs plotted represent a composite of 6–12 repeats. (B) PUNEL assay carried out on nondividing cells after
treatment for 1h with indicated doses of menadione and recovery in drug-free media for 75min. XKD and control cells were stained with DAB,
which produces a dark brown signal that is indicative of an accumulation of SSBs. (C) Percentage PUNEL positive XKD (black bar) or scramble
control (open bar) cells were estimated as a percent of total nondividing cells counted in each frame (B). Percentage PUNEL positive cells represent
the number of PUNEL positive cells relative to total cells counted. Averages and SDs plotted represent at least 50 cells scored per dose over three
repeats.
 P=0.007 and
  P=0.0004.
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combined results indicate that XRCC1 heterozygous neu-
rons are hypersensitive to menadione relative to their wild-
type counterparts (Figure 5A). At higher doses, the diﬀer-
ence in sensitivity of the heterozygous cells is most pro-
nounced, with  5-fold hypersensitivity at 100mM and a
30-fold increase in PI staining frequency at 300mM mena-
dione. Using a separate set of experimental animals (one
wild-type and three haploinsuﬃcient pups in this litter),
we also measured apoptosis and the accumulation of
DNA damage in isolated primary mouse granule neurons.
Consistent with the survival data, these studies revealed an
increase in both SSB accumulation ( 1.6- to 1.9-fold,
comparing the average percentage of PUNEL positive
cells in the heterozygous animals to the wild-type counter-
part at 50 or 300mM menadione; Figure 5B) and apoptosis
( 2.2- to 2.8-fold, derived as above using percentage of
caspase positive cells; Figure 5C) in the XRCC1 hetero-
zygous cells challenged with menadione. We note that
untreated wild-type and heterozygous cells exhibited simi-
lar growth and cell viability for up to 4 weeks in culture at
20% oxygen (Kulkarni, McNeill and Wilson, unpublished
observation).
Second, we determined the eﬀect of XRCC1-deﬁciency
on the DNA damage response of primary human fetal
neuronal cells using the PUNEL assay after exposure to
menadione. Immunocytochemical analysis of a mixed
glial–neuronal cell population infected with the
Figure 4. Response of XKD SH-SY5Y cells to other forms of oxidative stress. XKD (open square) and control (ﬁlled circle) cells in dividing
(left column) and nondividing (right column) states were treated with the indicated concentrations of paraquat-24h (B), arsenic-24h (B) and
hypoxanthine (for XOH system)-15min (C) and then examined for viability using the WST1 assay as described in Materials and methods section.
Viability for each dose was calculated as a percentage of the OD 450nm reading relative to the untreated cells. Averages and SDs plotted represent a
composite of 4–6 repeats.
Nucleic Acids Research, 2008, Vol. 36, No. 15 5117XRCC1-targeting shRNA lentivirus system (see above)
showed a signiﬁcant knockdown of the XRCC1 pro-
tein relative to the control virus (scramble-shRNA)
(Figure 6A). Neuronal cells were distinguished from
both glial cells and feeder layer astrocytes using a
neuron speciﬁc antibody probe (Figure 6B, ‘Tuj-1’
column). As seen in Figure 6B, at the lowest dose of mena-
dione tested (25mM), XKD human neuronal cells, showed
 4-fold greater frequency of DNA damage staining rela-
tive to the control cells following a 75min recovery period
in drug-free media (100 versus 27%, see Figure 6B). At
higher doses of 100mM (data not shown) and 400mM
(Figure 6B), the damage was found to be about equal
for the control and XKD cells, apparently reﬂecting a
near maximal level of DNA damage for both cell
populations.
DISCUSSION
XRCC1 is a critical scaﬀold protein that promotes eﬃ-
cient SSBR by coordinating the enzymatic processing of
nonconventional 30 or 50 DNA termini and SSB gaps (5,9).
Recent evidence has indicated that a defect in SSBR gives
rise to the neurodegeneration associated with the heredi-
tary disorders AOA1 and SCAN1 (9,12,18,38–42). Using
XRCC1 as a representative of global SSBR, we assessed
the role of this response in cellular protection against the
deleterious consequences of oxidative stress in both divid-
ing (undiﬀerentiated) and nondividing (diﬀerentiated)
neural cell populations. Prior work had demonstrated
that XRCC1 deﬁcient CHO cells are hypersensitive to
hydrogen peroxide (5), an observation that is consistent
with the sensitivity data herein using the XOH system
(Figure 4C, left), which creates a high level of extracellular
hydrogen peroxide as the toxic agent (35,43,44). The stu-
dies within are the ﬁrst to determine the consequences of
an XRCC1 defect on cellular sensitivity to the oxidizing
agents menadione, paraquat and arsenic.
Using the SH-SY5Y neuroblastoma cell line, which can
exist in both a dividing and nondividing state, we exam-
ined the eﬀects of lentiviral-mediated shRNA knockdown
of XRCC1 on cellular sensitivity to oxidative stress
induced by menadione, paraquat, arsenic and XOH. In
the case of the ﬁrst three agents, enhanced sensitivity
was seen primarily in the diﬀerentiated, nondividing cell
population, and was apparently related to a defect in
SSBR as evident from the inability of the menadione-
treated XKD cells to recover from induced DNA
damage (Figure 3B). The only exception to this ‘sensitivity
proﬁle’ was the XOH treatment, which caused reduced
viability of both dividing and nondividing XKD cells rela-
tive to the comparable scramble shRNA controls
Figure 5. Role of XRCC1 in stress resistance in wild type and hetero-
zygous mouse neuronal cells. (A) Primary mouse cerebellar granule cells
were treated with the oxidizing agent menadione for 1h at 378C at the
indicated concentrations, and then diﬀerentially stained for living and
dead cells. XRCC1 heterozygous cells (open square) showed reduced
viability as compared to wild type (ﬁlled circle). Viability for each
treatment was calculated as the percentage of live cells scored per
total cells scored. Averages and SDs plotted represent data from
three heterozygous and four wild-type pups with at least 50 cells
scored per dose, per pup. (B) Mouse cerebellar granule cells were
tested for accumulation of SSBs using the PUNEL assay after exposure
tomenadione. ‘% PUNEL positive cells’ wasscored as a percentage of the
total cells visualized in each frame. Values plotted represent averages and
SDs from at least 100 cells counted over three repeats. P-values were
determined using the t-test function in Excel, comparing the percentage
PUNEL positive cells for the single wild-type animal to the combined
measurements of the three heterozygous mice.
 P=0.002 and
  P=2.8E 05at the indicated menadione concentration. (C) Mouse cer-
ebellar granule cells were tested for apoptosis following treatment with
menadione. Activated caspases were visualized using ﬂuorescence micro-
scopy and ‘% caspase positive cells’ was calculated as percentage of total
cells scored. At least 100 cells were counted per treatment for the same
pups in panel B to arrive at the plotted averages and SDs. P-values were
determined as above, except comparing percentage caspase positive cells
of the single wild-type animal to the combined measurements of the three
heterozygous mice.
 P=7.2E 05 and
  P=0.0018 (B).
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tivity of nondividing XRCC1 deﬁcient cells to oxidative
stress is consistent with such cells lacking the alter-
native mechanisms present in dividing cells to resolve
SSBs (20).
The disparate proﬁle seen with the diﬀerent agents
above could stem from a diﬀerence in the types of ROS
formed and thus the types of DNA lesions introduced.
Both menadione and paraquat are redox-cycling agents
that generate signiﬁcant levels of intracellular superoxide
anions, as well as hydrogen peroxide and other radical
species, during their metabolism (34,35,44–46). Arsenic
induces the formation of primarily superoxide, singlet
oxygen, the peroxyl radical, nitric oxide, hydrogen perox-
ide, dimethylarsinic peroxyl radicals and the dimethylar-
sinic radical (47–49). For the XOH system, which
produces an extracellular ﬂux of superoxide anion radical
and hydrogen peroxide, the molecule most likely respon-
sible for the induction of oxidative DNA damage is
the latter diﬀusible species and its intracellular decompo-
sition products, mainly the hydroxyl radical (35,50,51).
Signiﬁcantly, it has been found that catalase, but not
superoxide dismutase, functions to suppress the chromo-
somal instability associated with XOH, whereas catalase
has no eﬀect on, and superoxide dismutase increases, the
instability seen with paraquat (35,43,44–51). These ﬁnd-
ings provide evidence that the diﬀering array of ROS
(possibly superoxide versus hydrogen peroxide) can give
rise to a disparate spectrum of genotoxic damage, and that
the constellation of DNA lesions (base modiﬁcations,
sugar damage and SSBs), in combination with the plat-
form of active repair responses, will dictate the overall
response of XRCC1 deﬁcient cells.
XRCC1 deﬁciency in primary, nondividing mouse cer-
ebellar granule and fetal human neuronal cells resulted in
impaired SSBR and reduced viability under conditions of
oxidative stress. Behavioral studies (i.e. rotorod tests) car-
ried out with 19- to 20-month-old XRCC1 heterozygous
mice have not, however, revealed spontaneous (i.e. non-
induced) motor incoordination relative to age-matched
wild-type animals (Paul Pistell, McNeill and Wilson,
unpublished data), consistent with the fact that untreated
mouse xrcc1
+/  neurons display a normal basal level of
DNA damage (Figure 5B). Katyal et al. recently reported
that mice deleted for tdp1, which results in defective SSBR
in neurons, exhibit an age-dependent progressive cerebelar
atrophy, but lack the severe motor incoordination seen
with SCAN1 patients, suggesting dissimilarity in the
mouse and human responses. Additional behavioral
and histopathological studies using both XRCC1-deﬁcient
and control mice following an external insult are nec-
essary to investigate further the contribution of XRCC1
and functional SSBR in the presentation or acceleration
of mammalian neurodegenerative disease. Notably,
human XKD fetal brain neurons showed a trend,
though not statistically signiﬁcant, towards increased
DNA damage in the untreated samples relative to the
controls (see Figure 6B), suggesting that there could
exist a set of ataxia patients that arise from genetic defects
in XRCC1.
Figure 6. Oxidative stress response in XKD human fetal brain neurons.
(A) Human fetal brain neuronal-glial cell populations were treated with
shRNA targeting XRCC1 or a scramble control shRNA via a lentivirus
delivery system (see Materials and methods section). Three days post-
infection, cells were ﬁxed and stained with DAPI (left column, ‘total
cells’) and for XRCC1 protein expression using an XRCC1-speciﬁc
antibody and a FITC-labeled secondary antibody (center column,
‘XRCC1’). Image shows decreased intensity of FITC staining in
XRCC1 shRNA targeted cells (lower panel), indicating signiﬁcant
knockdown of XRCC1. The merge of the DAPI and FITC signals is
shown to the right. (B) XKD or control human fetal brain neuronal–
glial cell populations were treated with the indicated concentrations of
menadione for 1h (left), allowed to recover in drug free media for
75min, ﬁxed and then examined for DNA damage and apoptosis
using the PUNEL assay (see Materials and methods section). The
Tuj-1 neuronal marker, coupled with a cy3 detection system, was
used to identify neuronal cells (left column, ‘Tuj-1’). FITC ﬂuorescence
indicates DNA damage accumulation and apoptotic cells (center
column). For untreated cells, out of 25 XKD cells counted nine were
PUNEL positive (36%) as compared to four of 27 (15%) scored for the
control cells (P=0.172). At 25mM menadione, out of 25 XKD cells
counted, all were PUNEL positive (100%), as compared to seven of 26
(27%) scored for the control cells (P=0.008). P-values were deter-
mined via chi-square contingency table analysis at http://www.physics.
csbsju.edu/stats/contingency_NROW_NCOLUMN_form.html.
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